Evidence map›Paper›PMID 42026086›Full record

ArticleNature communications2026

Phosphatidylserine-everted erythrocyte membrane vesicles enhance efferocytosis and remodeling of vascular grafts.

Zihao Wang, Quhan Cheng, Mengxue Zhou, Kexin Feng, Qi Chen, Yi Yuan, Shengmin Zhang, Deling Kong, Kai Wang, Jianglin Wang

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Nature communications, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Zihao Wang *Department of Biomedical Engineering, National Medical Products Administration (NMPA) Research Base of Regulatory Science for Medical Devices, Huazhong University of Science and Technology, Wuhan, China.
Quhan Cheng *Key Laboratory of Bioactive Materials Ministry of Education, College of Life Sciences, State Key Laboratory of Medicinal Chemical Biology, Nankai University, Tianjin, China.
Mengxue Zhou *Department of Biomedical Engineering, National Medical Products Administration (NMPA) Research Base of Regulatory Science for Medical Devices, Huazhong University of Science and Technology, Wuhan, China.
Kexin FengDepartment of Biomedical Engineering, National Medical Products Administration (NMPA) Research Base of Regulatory Science for Medical Devices, Huazhong University of Science and Technology, Wuhan, China.
Qi ChenDepartment of Biomedical Engineering, National Medical Products Administration (NMPA) Research Base of Regulatory Science for Medical Devices, Huazhong University of Science and Technology, Wuhan, China.
Yi YuanDepartment of Biomedical Engineering, National Medical Products Administration (NMPA) Research Base of Regulatory Science for Medical Devices, Huazhong University of Science and Technology, Wuhan, China.
Shengmin ZhangDepartment of Biomedical Engineering, National Medical Products Administration (NMPA) Research Base of Regulatory Science for Medical Devices, Huazhong University of Science and Technology, Wuhan, China.
Deling KongKey Laboratory of Bioactive Materials Ministry of Education, College of Life Sciences, State Key Laboratory of Medicinal Chemical Biology, Nankai University, Tianjin, China.ORCID http://orcid.org/0000-0002-2961-9267
Kai WangKey Laboratory of Bioactive Materials Ministry of Education, College of Life Sciences, State Key Laboratory of Medicinal Chemical Biology, Nankai University, Tianjin, China. 013053@nankai.edu.cn.ORCID http://orcid.org/0000-0003-3317-3509
Jianglin WangDepartment of Biomedical Engineering, National Medical Products Administration (NMPA) Research Base of Regulatory Science for Medical Devices, Huazhong University of Science and Technology, Wuhan, China. jwang520@hust.edu.cn.ORCID http://orcid.org/0000-0002-0733-2097

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Erythrocytes and erythrocyte membrane vesicles have shown promise for personalized drug delivery through passive immune evasion, yet their active role in immune phagocytosis remains largely unexplored. Here, we introduce a paradigm based on phosphatidylserine-everted erythrocyte membrane vesicles that trigger efferocytosis, enabling immune-mediated tissue regeneration rather than immune evasion. Incorporation of these phosphatidylserine-everted erythrocyte membrane vesicles into small-diameter vascular grafts markedly enhances endothelialization, suppresses calcification, and improves long-term patency in a rabbit carotid artery replacement model. Preclinical evaluation in a large canine model further demonstrates superior performance compared with clinically used expanded polytetrafluoroethylene grafts. This study establishes engineered phosphatidylserine-everted erythrocyte membrane vesicles as a versatile, customizable, and cost-effective biointerface for vascular grafts and other blood-contacting devices, providing a compelling strategy to harness innate immune mechanisms for regenerative medicine.

Indexed as

Blood Vessel ProsthesisEfferocytosisErythrocyte MembranePhosphatidylserinesVascular GraftingAnimalsCarotid ArteriesDogsHumansMalePhagocytosisRabbitsPhosphatidylserines

Identifiers

PMID42026086
PMCPMC13315726

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.